The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Reversal of experimental diabetic neuropathy by VEGF gene transfer
Open accessAbstract
The pathogenetic basis for diabetic neuropathy has been enigmatic. Using two different animal models of diabetes, we have investigated the hypothesis that experimental diabetic neuropathy results from destruction of the vasa nervorum and can be reversed by administration of an angiogenic growth factor. Nerve blood flow, as measured by laser Doppler imaging or direct detection of a locally administered fluorescent lectin analogue, was markedly attenuated in rats with streptozotocin-induced diabetes, consistent with a profound reduction in the number of vessels observed. A severe peripheral neuropathy developed in parallel, characterized by significant slowing of motor and sensory nerve conduction velocities, compared with nondiabetic control animals. In contrast, 4 weeks after intramuscular gene transfer of plasmid DNA encoding VEGF-1 or VEGF-2, vascularity and blood flow in the nerves of treated animals were similar to those of nondiabetic control rats; constitutive overexpression of both transgenes resulted in restoration of large and small fiber peripheral nerve function. Similar experiments performed in a rabbit model of alloxan-induced diabetes produced comparable results. These findings support the notion that diabetic neuropathy results from microvascular ischemia involving the vasa nervorum and suggest the feasibility of a novel treatment strategy for patients in whom peripheral neuropathy constitutes a secondary complication of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Dvorak, H. F., Brown, L. F., Detmar, M. J., & Dvořàk, A. M. (1995) · Europe PMC (PubMed Central) · Cited by 3,115
Joukov, V., Pajusola, K., Kaipainen, A., Chilov, D., Lahtinen, I., Kukk, E., Saksela, O., Kalkkinen, N., & Alitalo, K. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00359.x · Cited by 1,672
Adamis, A. P., Miller, J. W., Bernal, M.-T., D'Amico, D. J., Folkman, J., Yeo, T.-K., & Yeo, K.-T. (1994) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)75794-0 · Cited by 1,296
Nitric oxide synthase modulates angiogenesis in response to tissue ischemia.
Murohara, T., Asahara, T., Silver, M., Bauters, C., Masuda, H., Kalka, C., Kearney, M., Chen, D., Symes, J. F., Fishman, M. C., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1560 · Cited by 1,200
Self-citationBaumgartner, I., Pieczek, A., Manor, O., Blair, R., Kearney, M., Walsh, K., & Isner, J. M. (1998) · Circulation · doi:10.1161/01.cir.97.12.1114 · Cited by 1,098
Self-citationIsner, J. M., Pieczek, A., Schainfeld, R., Blair, R., Haley, L., Asahara, T., Rosenfield, K., Razvi, S., Walsh, K., & Symes, J. F. (1996) · The Lancet · doi:10.1016/s0140-6736(96)03361-2 · Cited by 989
Self-citationLosordo, D. W., Vale, P. R., Symes, J. F., Dunnington, C. H., Esakof, D. D., Maysky, M., Ashare, A. B., Lathi, K., & Isner, J. M. (1998) · Circulation · doi:10.1161/01.cir.98.25.2800 · Cited by 987
Self-citation
Cited by
Feldman, E. L., Callaghan, B. C., Pop-Busui, R., Zochodne, D. W., Wright, D. E., Bennett, D. L., Bril, V., Russell, J. W., & Viswanathan, V. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0092-1 · Cited by 1,697
Tepper, O. M., Galiano, R. D., Capla, J. M., Kalka, C., Gagne, P. J., Jacobowitz, G. R., Levine, J. P., & Gurtner, G. C. (2002) · Circulation · doi:10.1161/01.cir.0000039526.42991.93 · Cited by 1,448
Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum?
Chawla, R., Chawla, A., & Jaggi, S. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.183480 · Cited by 1,106
Molecular Understanding of Hyperglycemia's Adverse Effects for Diabetic Complications
Sheetz, M. J. (2002) · JAMA · doi:10.1001/jama.288.20.2579 · Cited by 1,002
Boulton, A. J. M., Malik, R. A., Arezzo, J. C., & Sosenko, J. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1458 · Cited by 913
Galiano, R. D., Tepper, O. M., Pelo, C. R., Bhatt, K. A., Callaghan, M., Bastidas, N., Bunting, S., Steinmetz, H. G., & Gurtner, G. C. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63754-6 · Cited by 798
From angiogenesis to neuropathology
Greenberg, D. A., & Jin, K. (2005) · Nature · doi:10.1038/nature04481 · Cited by 532
Blood vessels and nerves: common signals, pathways and diseases
Carmeliet, P. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1158 · Cited by 516
VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection
Storkebaum, E., Lambrechts, D., & Carmeliet, P. (2004) · BioEssays · doi:10.1002/bies.20092 · Cited by 507
The Pathologic Continuum of Diabetic Vascular Disease
Orasanu, G., & Plutzky, J. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.09.055 · Cited by 487
Role and Therapeutic Potential of VEGF in the Nervous System
Ruiz de Almodovar, C., Lambrechts, D., Mazzone, M., & Carmeliet, P. (2009) · Physiological Reviews · doi:10.1152/physrev.00031.2008 · Cited by 448
Tepper, O. M., Capla, J. M., Galiano, R. D., Ceradini, D. J., Callaghan, M. J., Kleinman, M. E., & Gurtner, G. C. (2005) · Blood · doi:10.1182/blood-2004-03-1051 · Cited by 445
Microvascular Dysfunction in Diabetes Mellitus and Cardiometabolic Disease
Horton, W. B., & Barrett, E. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa025 · Cited by 424
Gene transfer as a tool to induce therapeutic vascular growth
Ylä-Herttuala, S., & Alitalo, K. (2003) · Nature Medicine · doi:10.1038/nm0603-694 · Cited by 404
Vascular endothelial growth factor: a neurovascular target in neurological diseases
Lange, C., Storkebaum, E., de Almodóvar, C. R., Dewerchin, M., & Carmeliet, P. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.88 · Cited by 382
Netrins Promote Developmental and Therapeutic Angiogenesis
Wilson, B. D., Ii, M., Park, K. W., Suli, A., Sorensen, L. K., Larrieu-Lahargue, F., Urness, L. D., Suh, W., Asai, J., Kock, G. A. H., et al. (2006) · Science · doi:10.1126/science.1124704 · Cited by 352
Self-citationNeurovascular signalling defects in neurodegeneration
Zacchigna, S., Lambrechts, D., & Carmeliet, P. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2336 · Cited by 345
Challenges of neuropathic pain: focus on diabetic neuropathy
Rosenberger, D. C., Blechschmidt, V., Timmerman, H., Wolff, A., & Treede, R.-D. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02145-7 · Cited by 325
Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily
Bierhaus, A., Haslbeck, K.-M., Humpert, P. M., Liliensiek, B., Dehmer, T., Morcos, M., Sayed, A. A. R., Andrassy, M., Schiekofer, S., Schneider, J. G., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci18058 · Cited by 299
Bansal, V, Kalita, J., & Misra, U. K. (2006) · Postgraduate Medical Journal · doi:10.1136/pgmj.2005.036137 · Cited by 297
Yoon, Y.-S., Uchida, S., Masuo, O., Cejna, M., Park, J.-S., Gwon, H.-C., Kirchmair, R., Bahlman, F., Walter, D., Curry, C., et al. (2005) · Circulation · doi:10.1161/01.cir.0000162472.52990.36 · Cited by 288
Self-citationVEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema
Yoon, Y.-S., Murayama, T., Gravereaux, E., Tkebuchava, T., Silver, M., Curry, C., Wecker, A., Kirchmair, R., Hu, C. S., Kearney, M., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci15830 · Cited by 270
Self-citationJagodic, M. M., Pathirathna, S., Nelson, M. T., Mancuso, S., Joksovic, P. M., Rosenberg, E. R., Bayliss, D. A., Jevtovic-Todorovic, V., & Todorovic, S. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4866-06.2007 · Cited by 268
Nerve Growth Factor Promotes Angiogenesis and Arteriogenesis in Ischemic Hindlimbs
Emanueli, C., Salis, M. B., Pinna, A., Graiani, G., Manni, L., & Madeddu, P. (2002) · Circulation · doi:10.1161/01.cir.0000033971.56802.c5 · Cited by 267
Zachary, I. (2005) · Neurosignals · doi:10.1159/000088637 · Cited by 266
Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders
Carmeliet, P., & Storkebaum, E. (2002) · Seminars in Cell & Developmental Biology · doi:10.1006/scdb.2001.0290 · Cited by 252
VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond
Giacca, M., & Zacchigna, S. (2012) · Gene Therapy · doi:10.1038/gt.2012.17 · Cited by 252
Can VEGF reverse diabetic neuropathy in human subjects?
Veves, A., & King, G. L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13038 · Cited by 88
Paracrine control of vascularization and neurogenesis by neurotrophins
Emanueli, C., Schratzberger, P., Kirchmair, R., & Madeddu, P. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705458 · Cited by 62
“Recently, Schratzberger et al. (2001) demonstrated that the destruction of the vasa nervorum in two different animal models of experimental diabetic neuropathy induced by streptozotocin or alloxan can be reversed by administration of VEGF.”
BackgroundSelf-citation
Metadata
- Authors
- Schratzberger, P., Walter, D. H., Rittig, K., Bahlmann, F. H., Pola, R., Curry, C., Silver, M., Krainin, J. G., Weinberg, D. H., Ropper, A. H., & Isner, J. M.
- Venue
- Journal of Clinical Investigation
- Published
- 2001-05-01
- Volume
- 107
- Issue
- 9
- Pages
- 1083-1092
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2012018288
- Cited by
- 310
- References
- 42
- FWCI
- 11.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.